The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage Augustas Beiša1, Mindaugas.

Slides:



Advertisements
Similar presentations
Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Advertisements

Thyroid nodules - medical and surgical management JRE DavisNR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary.
Lateral neck dissection for papillary thyroid cancer
AJCC TNM Staging 7th Edition Thyroid Case #3
Breast Cancer in Pregnancy
Clinical Significance of Preoperative 18F-FDG PET Non- Avidity in Papillary Thyroid Carcinoma Do Hoon Koo 1, Ho-Young Lee 2, Kyu Eun Lee 3,4, So Won Oh.
Maria Chiara Zatelli Sezione di Endocrinologia Dip. di Scienze Biomediche e Terapie Avanzate Università di Ferrara Università di Ferrara Direttore: Prof.
Dr. LP Si Yan Chai Hospital. Background With the increasing use of imaging modalities, more and more clinically inconspicuous thyroid lesions are discovered.
Papillary Microcarcinoma of the Thyroid T.T. Law Queen Mary Hospital Joint Hospital Surgical Grand Round 16th January, 2010.
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
Thyroid nodule History History Physical examination Physical examination –Euthyroid –Hypothyroid –Hyperthyroid Labs Labs –TSH –(antibodies)
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Minimally Invasive Follicular Carcinoma: A Cytological and Histological Challenge David Poller, Queen Alexandra Hospital,Portsmouth, UK.
Emad Raddaoui, MD, FCAP, FASC Associate Professor; Consultant Histopathology & Cytopathology.
THYROID NODULES AND NEOPLASMS Emad Raddaoui, MD, FCAP, FASC Associate Professor; Consultant Histopathology & Cytopathology.
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Approach.
Thyroid Stuff Cytopathology & Pathology Ryan Orosco Sept 2013.
Ian Jaffee, MD FCAP Director of Cytopathology
Thyroid nodules and neoplasms EMAD RADDAOUI, MD, FCAP, FASC ASSOCIATE PROFESSOR; CONSULTANT HISTOPATHOLOGY & CYTOPATHOLOGY.
ד"ר חגי מזא"ה כירורגיה אנדוקרינית מבואות כירורגיה שנה ד'
Approach to a thyroid nodule
Approach to the Thyroid Nodule
Principles of Surgical Oncology Salah R. Elfaqih.
Principles of Surgical Oncology Salah R. Elfaqih.
Thyroid Nodules Hollis Moye Ray, MD SEAHEC Internal Medicine June 3, 2011.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
11th Biennial Meeting of the International Gynecologic Cancer Society 11th Biennial Meeting of the International Gynecologic Cancer Society Semih Gorgulu,
NYU Medicine Grand Rounds Clinical Vignette Jenny Ukena, PGY2 9/18/2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Principles of Surgical Oncology Done by : 428 surgery team surgery team.
Evaluation of Thyroid Nodules
The role of Endoscopy in Gastric Cancer Fergal Donnellan Gastroenterologist VGH.
Principles of Surgical Oncology
1. Clinical Impression? Differentials?. Thyroid Carcinoma commonly manifests as a painless, palpable, solitary thyroid nodule The patient's age at presentation.
Treatment of thyroid nodules Depends on: –FNA cytological examination –Uptake of radioiodine –Size and patient preferences.
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Pathology of thyroid 3 Dr: Salah Ahmed. Follicular adenoma - are benign neoplasms derived from follicular epithelium - are usually solitary - the majority.
Maria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli.
CLINICAL ASPECT OF GRADING AND STAGING Hanggoro Tri Rinonce, MD, PhD Department of Anatomical Pathology Faculty of Medicine, Gadjah Mada University.
갑상선 결절 및 암의 최신 치료지침 분당서울대학교병원 내과 연수강좌 분당서울대학교병원 내분비내과 문재훈.
Evaluation of Thyroid Nodule with US and FNA
R2 Jaemin Kim/Prof. Seungjoon Oh Journal conference 1.

Dr. Usha Sarma, Asstt. Professor, Dr. U. C. Dutta, Prof & Head, Pathology Deptt Gauhati Medical College FNAC of Thyroid Lesion 5 Years retrospective study.
The Role of Repeat Fine Needle Aspiration in Improving Diagnostic Accuracy in Thyroid Masses 1Laura Allen, 2Ayham Al Afif, 2Matthew H Rigby, 3Martin J.
Management of Thyroid Nodules Detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement Radiology 2005; 237: Presented.
Hua G, Hier M, Forest VI, Mlynarek A, Payne R.
Follicular variant of papillary thyroid carcinoma
Discussion & Conclusion Predictives of Meningioma Grading
Zehra Nihal Dolgun, Ahmet Salih Altintas, Cihan Inan, Petek Balkanli
Molecular Markers in Thyroid Disease Yeah or Meh?
Coexistence of chronic lymphocytic thyroiditis and well-differentiated thyroid cancer ( A prospective clinical study) Dimitrios Askitis1, Eleni Eufraimidou1,
NIFTP Bijan Iraj,MD Assistant Professor of Internal Medicine and Endocrinology Department of Endocrinology and Metabolism Isfahan Medical.
Prognosis of younger patients in non-small cell lung cancer
Table (1):Relation between lymph node and molecular subtypes.
Figure 1. BRAF V600E mutation analysis in PTC
MEDULLARY THYROID CANCER
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules  Kyung Sun Park, Young L. Oh, Chang-Seok Ki,
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Cancer Staging.
郭其毓 劉建良 劉滄柏 林鉷彬 柯文清 鄭世平 蔡家騏 何恭誠
Dr T P E Wells 13 July 2018 Breast SSG Bath
Cheng-Chiao Huang, MD, MSc
Thoracoscopic and laparoscopic lymph node staging in esophageal cancer: do clinicopathological factors affect the outcome?  Mark J Krasna, MD, Xiaolong.
Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for Small Pulmonary Lesions with Ground-Glass Attenuation  Chia-Hung Lu, MD, FRCR, Cheng-Hsiang.
AMR Seminar Symposium Split, Croatia Case #63
Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed  Emanuela Taioli, MD, PhD, Raja Flores, MD 
It’s All in the “Swerve of the Curve”
Surgical resection of metachronous liver metastases
Survival of Patients With Unsuspected pN2 Non-Small Cell Lung Cancer After an Accurate Preoperative Mediastinal Staging  Carme Obiols, MD, Sergi Call,
Presentation transcript:

The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage Augustas Beiša1, Mindaugas Kvietkauskas1, Virgilijus Beiša1, Mindaugas Stoškus2, Elvyra Ostanevičiūtė3, Eugenijus Jasiūnas4, Laimonas Griškevičius2,5, Kęstutis Strupas1 1 Centre of Abdominal Surgery, Vilnius University, Vilnius, Lithuania 2 Centre of Haematology, Oncology and Transfusion Medicine, Vilnius University, Vilnius, Lithuania 3 Centre of Laboratory Medicine, Vilnius University, Vilnius, Lithuania 4 Mykolas Romeris University, Vilnius, Lithuania 5 Centre of Internal, Family Medicine and Oncology, Vilnius University, Vilnius, Lithuania Introduction Approximately 10% of all thyroid cancers have a poor prognosis, making it important to identify clinicopathological factors that could facilitate better prediction of patient prognosis and planning of appropriate treatment. We hypothesized that preoperative determination of the Bethesda category of fine-needle aspiration (FNA) biopsy specimens and its association with BRAF mutation would be an informative for predicting the stage of papillary thyroid cancer (PTC), and it could assist in defining the optimal scope of initial surgical and medical managements for PTC. Figure 1. Flow diagram of study. 308 Patients from AUS/FLUS, FN/SFN, SMC, and PMC groups had a thyroid surgery 176 AUS/FLUS and FN/SFN patients underwent histological examination 132 SMC and PMC patients underwent histological examination 139 Were excluded: 131 Benign lesion 5 Follicular TC 1 Medullary TC 1 Anaplastic TC 1 Lymphoma   26 Were excluded: 14 Benign lesion 6 Follicular TC 5 Medullary TC 1 Anaplastic TC Methods A prospective study analyzed patients who had US suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from AUS/FLUS, FN/SFN, SMC, and PMC groups were examined for the BRAF mutation and had a thyroid surgery. Demographical, histological features (tumor size, extrathyroidal extension, lymphovascular invasion, lymph nodes metastases, R1 resection, multifocality, and PTC type) and stage of the disease were evaluated for PTC patients in accordance to the Bethesda category and its association with BRAF mutation. 37 Were diagnosed with PTC 106 Were diagnosed with PTC Table 2. Patients diagnosed with PTC demographics and histologic features according to the Bethesda category (n=143).   Bethesda Category Value of P Odds ratio (95% CI) AUS/FLUS and FN/SFN (n=37) SMC and PMC (n=106) Tumor size (cm) 1 (0.3-3.8) 1.5 (0.3-7) 0.028 0.49 (Eta) Extrathyroidal extension (n) 11 (29.7%) 50 (47.2%) 0.065 2.11 (0.95-4.7) Lymph node metastases (n) 5 (13.5%) 44 (41.5%) 0.002 4.54 (1.64-12.58) PTC stage (n) I-II III-IVA 30 (81.1%) 7 (18.9%) 58 (54.7%) 48 (45.3%) 0.005 3.55 (1.43-8.79) Results Three hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC (Figure 1). In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I-II stage of PTC was diagnosed for 88 (61.5%) patients and III-IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, BRAF positive, and III-IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups (Table 2). When comparing 27 (18.9%) BRAF negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF negative patients from the SMC and PMC groups and all BRAF positive patients, the prediction of more aggressive histological features and stage was slightly improved (Table 3). Table 3. Patients diagnosed with PTC demographics and histologic features according to association of the Bethesda category and BRAF mutation (n=143).   Groups Value of P Odds ratio (95% CI) AUS/FLUS and FN/SFN with BRAF negative (n=27) AUS/FLUS and FN/SFN with BRAF positive or SMC and PMC with any BRAF (n=116) Tumor size (cm) 0.8 (0.3-3.8) 1.5 (0.3-7) 0.105 0.46 (Eta) Extrathyroidal extension (n) 7 (25.9%) 54 (46.6%) 0.051 2.49 (0.98-6.34) Lymph node metastases (n) 2 (7.4%) 47 (40.5%) 0.001 8.51 (1.92-37.67) PTC stage (n) I-II III-IVA 23 (85.2%) 4 (14.8%) 65 (56%) 51 (44%) 0.005 4.51 (1.47-13.87) Conclusions Higher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction. Beiša, A., Kvietkauskas, M., Beiša, V. et al. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg (2017). doi:10.1007/s00423-017-1560-2